Lake Street analyst Brooks O’Neil maintained a Buy rating on Electromed (ELMD – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $17.51.
According to TipRanks, O’Neil is an analyst with an average return of -1.1% and a 42.92% success rate. O’Neil covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care, ModivCare, and Augmedix.
Currently, the analyst consensus on Electromed is a Moderate Buy with an average price target of $26.00.
Based on Electromed’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $13.87 million and a net profit of $1.49 million. In comparison, last year the company earned a revenue of $12.07 million and had a net profit of $1.08 million
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ELMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Electromed (ELMD) Company Description:
Electromed, Inc. engages in the development, manufacture, marketing, and sale of medical equipment. It offers smartvest, and airways clearance system to patients with compromised pulmonary function. It focuses on building market awareness, and acceptance of its products and services with physicians, clinicians, patients, and third-party payers. The company was founded by Robert D. Hansen and Craig N. Hansen in 1992 and is headquartered in New Prague, MN.
